Cargando…

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

BACKGROUND: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity. CASE PRESENTATION: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domenico, Ciliberto, Antonella, Ierardi, Benedetto, Caroleo, Luigi, Scalise, Antonio, Cimellaro, Lidia, Colangelo, Giuseppe, Spaziano, Gallelli, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864607/ https://www.ncbi.nlm.nih.gov/pubmed/31113346 http://dx.doi.org/10.2174/1574886314666190522094713

Ejemplares similares

Panitumumab-Induced Acneiform Rash in a Patient with Metastatic Colon Adenocarcinoma
por: Martins-Filho, Paulo Ricardo Saquete, et al.
Publicado: (2013)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients
por: Perticone, Maria, et al.
Publicado: (2016)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer
por: Bouché, Olivier, et al.
Publicado: (2019)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
por: Jin, Haoxing D., et al.
Publicado: (2020)

Mesenteric panniculitis presenting with acute non-occlusive colonic ischemia
por: Amor, Florian, et al.
Publicado: (2011)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
por: Kasagi, Yuta, et al.
Publicado: (2013)

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer
por: Koumaki, Dimitra, et al.
Publicado: (2020)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

The Role of MMPs in the Era of CFTR Modulators: An Additional Target for Cystic Fibrosis Patients?
por: Esposito, Renata, et al.
Publicado: (2023)

Wolf’s Panniculitis
por: Chokoeva, Anastasiya Atanasova, et al.
Publicado: (2017)

Mesenteric panniculitis
por: Kgomo, Mpho, et al.
Publicado: (2017)

Panniculitis in Children
por: Moulonguet, Isabelle, et al.
Publicado: (2021)

Mesenteric panniculitis of the sigmoid colon: a case report and review of the literature
por: Popkharitov, Angel I, et al.
Publicado: (2007)

Annual report on adverse events related with vaccines use in Calabria (Italy): 2012
por: Staltari, Orietta, et al.
Publicado: (2013)

Recurrence of atrial fibrillation after switching from brand to generic atenolol
por: Gallelli, Luca, et al.
Publicado: (2015)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

Lesser Omental Panniculitis
por: Nakamura, Masaharu, et al.
Publicado: (2020)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
por: Patel, Shiven B, et al.
Publicado: (2015)

Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW
por: Krishnan, Giri, et al.
Publicado: (2021)

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Subcutaneous Panniculitis-Like T Cell Lymphoma Mimicking Early-Onset Nodular Panniculitis
por: Shen, Guifen, et al.
Publicado: (2016)

Pancreatic panniculitis: the “bright” side of the moon in solid cancer patients
por: Guanziroli, Elena, et al.
Publicado: (2018)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

The coexistence of lupus erythematosus panniculitis and subcutaneous panniculitis-like T-cell lymphoma in the same patient
por: Wu, Xinyu, et al.
Publicado: (2018)

Immunogenicity of panitumumab in combination chemotherapy clinical trials
por: Weeraratne, Dohan, et al.
Publicado: (2011)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer
por: Battaglin, Francesca, et al.
Publicado: (2019)

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
por: Liao, Michael Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qq8ikdli36v28las9l98a9tjkn